Abstract
BackgroundThis study had a threefold aim: to test the value of stakeholder involvement in HTA to reduce evidence gaps and interpret findings; and to assess a medical device by applying the EUnetHTA Core Model (CM) in South Africa and thus ultimately provide a first overview of evidence for potential widespread adoption of the technology in a primary health care (PHC) setting. Used in primary healthcare setting for obstetric use, the technology under assessment is a low-cost continuous wave Doppler ultrasound (DUS).MethodsThe scoping of the assessment was defined by involving policy makers in selecting the domains and corresponding questions relevant to the ultrasound and its use. Additionally, hospital managers were invited to respond to dichotomous questions on the criteria for procurement. To substantiate evidence obtained from an initial literature review, different stakeholders were identified and consulted. The evidence generated fromall steps was used to populate the high-ranked assessment elements of the CM.ResultsThe HTA on continuous-wave DUS incorporated the evidence on organizational, ethical, and social value of its use together with effectiveness, safety, and cost-effectiveness of the technology. The domains on “health problem” and “safety” had a higher rank than the rest of the nine domains. Unexplained fetal mortality is the largest single contributor to perinatal deaths in South Africa. Pregnant women in PHC setting were examined using a continuous-wave DUS, after their routine antenatal visit. The healthcare professionals interviewed, indicated the benefit in the use of continuous-wave DUS in the PHC setting and the need for training.ConclusionsCollection and generation of evidence based on the HTA CM and the chosen decision criteria provided a generalized but structured guidance on the methodology. Several questions were not applicable for the technology and the context of its use and elimination of those that are inappropriate for the African context, resulted in a pragmatic solution. Engaging and consulting local stakeholders was imperative to understand the context, reduce evidence gaps, and address the uncertainties in the evidence, ultimately paving the way for technology adoption. Given the ongoing studies and the evolving evidence base, the potential of this technology should be reassessed.
Highlights
This study had a threefold aim: to test the value of stakeholder involvement in Health Technology Assessment (HTA) to reduce evidence gaps and interpret findings; and to assess a medical device by applying the EUnetHTA Core Model (CM) in South Africa and provide a first overview of evidence for potential widespread adoption of the technology in a primary health care (PHC) setting
This study aims to: (a) Evaluate a technology, the Umbiflow, which is at an earlier stage of adoption, by application of the EUnetHTA Core Model in a non-European setting; (b) Demonstrate the value of stakeholder engagement and consultation to mitigate evidence gaps, address uncertainties, and interpret findings when evaluating technologies in an emerging setting with limited resources; (c) Provide a first overview of evidence for the potential widespread adoption of UmbiflowTM in PHC in South Africa
There was a variance observed in the Interquartile ranges (IQR). 5 of the 9 domains including current use of the technology (CUR) and SAF reached a consensus with a strong agreement (IQR between 4 and 5) on their relevance
Summary
This study had a threefold aim: to test the value of stakeholder involvement in HTA to reduce evidence gaps and interpret findings; and to assess a medical device by applying the EUnetHTA Core Model (CM) in South Africa and provide a first overview of evidence for potential widespread adoption of the technology in a primary health care (PHC) setting. Maternal and child mortality remain unacceptably high, despite significant progress in recent years [1]; reducing them remains a priority for many governments. Maternal mortality amounted to 533 deaths per 100,000 live births in 2017, compared to 11 deaths per 100,000 live births among high-income countries and 211 deaths per 100,000 live births globally [2]. SSA countries are still far from achieving this goal [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.